BioForce Nanosciences is a subsidiary of Nanosciences Holdings, Inc. The subsidiary develops and commercializes nanotech instruments, and associated consumables and applications for the life sciences sector.
BioForce Nanosciences was given a “buy” rating and a $1.79 target price after record revenue was reported, demand increased for their Nano eNable product, the potential of a private placement, and the announcement of a new Chief Financial Officer.
Unlike many of the self-proclaimed nanotech companies, BioForce has an actual product which is generating profits. The management has embraced a “practical nanotechnology” business strategy, and is executing the focused business plan.
Let us hear your thoughts below: